NYSE:FMS - Fresenius Medical Care AG & Co. Stock Price, Forecast & News

Fresenius Medical Care AG & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "FMS."

Fresenius Medical Care AG & Co. announced an annual dividend on Thursday, May 9th. Stockholders of record on Monday, May 20th will be given a dividend of $0.6551 per share on Friday, May 31st. This represents a dividend yield of 1.59%. The ex-dividend date of this dividend is Friday, May 17th. This is a positive change from Fresenius Medical Care AG & Co.'s previous annual dividend of $0.44. View Fresenius Medical Care AG & Co.'s Dividend History.

Fresenius Medical Care AG & Co. (NYSE:FMS) released its quarterly earnings data on Monday, August, 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.49 by $0.01. The firm earned $4.42 billion during the quarter, compared to the consensus estimate of $4.54 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.32% and a net margin of 6.87%. View Fresenius Medical Care AG & Co.'s Earnings History.

Fresenius Medical Care AG & Co. is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Fresenius Medical Care AG & Co..

10 equities research analysts have issued 12-month price targets for Fresenius Medical Care AG & Co.'s shares. Their forecasts range from $40.23 to $54.00. On average, they anticipate Fresenius Medical Care AG & Co.'s share price to reach $46.18 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price. View Analyst Price Targets for Fresenius Medical Care AG & Co..

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius Medical Care AG & Co. in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fresenius Medical Care AG & Co..

Press coverage about FMS stock has trended neutral on Tuesday, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fresenius Medical Care AG & Co. earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Fresenius Medical Care AG & Co..

Fresenius Medical Care AG & Co. saw a decrease in short interest in January. As of January 31st, there was short interest totalling 608,700 shares, a decrease of 24.1% from the January 15th total of 802,300 shares. Based on an average daily trading volume, of 303,600 shares, the short-interest ratio is presently 2.0 days. Currently, 0.1% of the company's stock are sold short. View Fresenius Medical Care AG & Co.'s Current Options Chain.

Some companies that are related to Fresenius Medical Care AG & Co. include Davita (DVA), Progyny (PGNY), Tivity Health (TVTY), HemaCare (HEMA), Catasys (CATS), American Renal Associates (ARA), Emmaus Life Sciences (EMMA), Baudax Bio (BXRX), Pacific Health Care Organization (PFHOD), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX) and American Caresource (GNOW).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius Medical Care AG & Co. investors own include Petra Diamonds (PDL), Energy Transfer LP Unit (ET), Teva Pharmaceutical Industries (TEVA), Novartis (NVS), AbbVie (ABBV), AT&T (T), Abbott Laboratories (ABT), Pfizer (PFE), Ford Motor (F) and Gilead Sciences (GILD).

Fresenius Medical Care AG & Co.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.22%), Thornburg Investment Management Inc. (0.11%), Bank of America Corp DE (0.06%), NWQ Investment Management Company LLC (0.05%), Goldman Sachs Group Inc. (0.04%) and Jarislowsky Fraser Ltd (0.03%).

FMS stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Thornburg Investment Management Inc., Bank of America Corp DE, NWQ Investment Management Company LLC, Franklin Resources Inc., Renaissance Technologies LLC, Envestnet Asset Management Inc. and Eagle Global Advisors LLC.

FMS stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Connor Clark & Lunn Investment Management Ltd., DCF Advisers LLC, Geode Capital Management LLC, Marshall Wace LLP, Goldman Sachs Group Inc., Marshall Wace North America L.P. and Campbell & CO Investment Adviser LLC.

Shares of FMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FMS stock can currently be purchased for approximately $39.72.

Fresenius Medical Care AG & Co. has a market capitalization of $24.06 billion and generates $19.58 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $2.53 on an earnings per share basis. Fresenius Medical Care AG & Co. employs 112,658 workers across the globe.View Additional Information About Fresenius Medical Care AG & Co..

The official website for Fresenius Medical Care AG & Co. is http://www.freseniusmedicalcare.com/.

Fresenius Medical Care AG & Co.'s mailing address is ELSE-KROENER STRASSE 1, BAD HOMBURG 2M, 61352. The company can be reached via phone at 49-6172-608-2522 or via email at [email protected]